AcelRx Pharmaceuticals

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals was established in Redwood City, California in 2005 by anesthesiologist Dr. Pamela Palmer and entrepreneur Thomas Schreck. The founding thesis centered on the gap between potent intravenous pain relief and the logistical burden it imposes in hospitals, emergency departments, and battlefield medicine. Palmer brought direct clinical insight into opioid pharmacology, while Schreck contributed drug-delivery platform expertise that ultimately produced the company's proprietary single-dose applicator technology. The core commercial asset is DSUVIA (sufentanil sublingual tablet), approved by the FDA in November 2018 for moderate-to-severe acute pain in adults when administered by a healthcare professional. A second product, Zalviso (sufentanil sublingual tablet system), is designed for patient-controlled analgesia in hospital settings and received European Medicines Agency approval, though U.S. regulatory clearance took longer. AcelRx's strategy deliberately avoids the consumer-opioid market, instead targeting monitored medical environments where the risk of diversion is protocol-managed. Deployment concentrates on the Department of Defense—which purchased DSUVIA for battlefield use under a multi-year contract—alongside select hospital systems and ambulatory surgery centers in the United States. The geographic footprint spans North America and Europe, with EU commercialization handled through distribution partners. As a commercial-stage micro-cap, AcelRx does not frame itself around assets under management. The company funds operations through equity raises, royalty monetization agreements, and product revenue. In September 2023 the firm merged with Tetraphase Pharmaceuticals, adding Xerava, a FDA-approved antibiotic for complicated intra-abdominal infections, to its commercial portfolio. Headcount runs in the dozens, focused on medical affairs, commercial sales, and regulatory maintenance. There is no dedicated venture arm or corporate venture fund, though the management team has historically evaluated strategic acquisitions of on-market specialty assets to broaden the hospital-focused product basket. AcelRx's structural differentiator is its status as a publicly traded specialty pharmaceutical company with a real product on formulary rather than a preclinical biotech betting on binary trial outcomes. The post-merger entity now carries two distinct commercialized drugs, each addressing narrow hospital use cases that do not compete with one another. Succession and governance lean on the CEO Vincent Angotti, who took the role in 2022, while Palmer remains as Chief Medical Officer, preserving clinical continuity inside a commercial-stage organization. The next observable milestone is the integration of the Tetraphase assets and whether the combined sales infrastructure can push Xerava and DSUVIA across profitability thresholds without further shareholder dilution.